Vascugen
Madison, US · Founded 2017 · 1 known investors
Vascugen develops an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell therapy intended to form new blood vessels and restore microvascular circulation in oxygen-starved tissues. It targets diabetic and arterial disease patients at high risk of limb amputation, and handles development from R&D through cGMP manufacturing.
Founders & leadership
Vascugen was founded in 2017 by Marvin Yoder and Mervin C. Yoder.
MY
Marvin YoderCo-founder
MC
Mervin C. YoderScientific Founder
CC
Carter CliffNamed on SEC filing
TN
Tom NovakNamed on SEC filing
JK
Jeffrey KennedyNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2019
▶$10MraisedAug 2020 · 6 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marvin YoderDirector
- Carter CliffExecutive Officer, Director
- Tom NovakDirector
- Jeffrey KennedyDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vascugen do?
- Vascugen develops an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell therapy intended to form new blood vessels and restore microvascular circulation in oxygen-starved tissues. It targets diabetic and arterial disease patients at high risk of limb amputation, and handles development from R&D through cGMP manufacturing.
- Who founded Vascugen?
- Vascugen was founded by Marvin Yoder, Mervin C. Yoder in 2017.
- Who are Vascugen's investors?
- Vascugen's investors include IU Ventures.
- How much funding has Vascugen raised?
- Vascugen has disclosed $10M raised across 1 round.
- Where is Vascugen headquartered?
- Vascugen is headquartered in Madison, US.